Neutralization and enhancement of HIV-1 infection by sera from HIV-1 infected individuals who progress to disease at different rates

Virology

Volumn 273, Issue 1, 2000, Pages 52-59

  Jolly, Pauline E ^a   Weiss, Heidi L ^b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY RESPONSE; ARTICLE; CLINICAL ARTICLE; DILUTION; DISEASE COURSE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNITY; PRIORITY JOURNAL; SERUM; VIRUS INFECTIVITY; VIRUS NEUTRALIZATION; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; RNA VIRUSES;

EID: 0034691584     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.2000.0401     Document Type: Article

References (41)

1. Barrett A. D. T., Gould E. A. Antibody-mediated early death in vivo after infection with yellow fever virus. J. Gen. Virol. 67:1986;2539-2542.
2. Bolognesi D. P. Do antibodies enhance the infection of cells by HIV? Nature. 340:1989;431-432.
3. Burke D. S. Human HIV vaccine trials: Does antibody-dependent enhancement pose a genuine risk? Perspect. Biol. Med. 35:1992;511-530.
4. Cao Y., Qin L., Zhang L., Safrit J., Ho D. D. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. N. Engl. J. Med. 332:1995;201-208.
5. Carotenuto P., Looij D., Keldermans L., de Wolf F., Goudsmit J. Neutralizing antibodies are positively associated with CD4+ T-cell counts and T-cell function in long-term AIDS-free infection. AIDS. 12:1998;1591-1600.
6. Cecilia D., Kleeberger C., Munoz A., Giorgi J. V., Zolla-Pazner S. A longitudinal study of neutralizing antibodies and disease progression in HIV-1-infected subjects. J. Virol. 179:1999;1365-1374.
7. Chin J., Magoffin R. L., Shearer L. A., Schieble J. H., Lennette E. H. Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population. Am. J. Epidemiol. 89:1969;449-463.
8. Dolin R., Graham B. S., Greenberg S. B., Tacket C. O., Belshe R. B., Midthun K., Clements M. L., Gorse G. J., Horgan B. W., Atmar R. L., Karzon D. T., Bonnez W., Fernie B. F., Montefiori D. C., Stablein D. M., Smith G. E., Koff W. C. The safety and immunogenicity of a human immunodeficiency virus type 1 (HIV-1) recombinant gp160 candidate vaccine in humans. Ann. Intern. Med. 114:1991;119-127.
9. Eaton A. M., Ugen K. E., Weiner D. B., Wildes T., Levy J. A. An anti-gp41 human monoclonal antibody that enhances HIV-1 infection in the absence of complement. AIDS Res. Hum. Retroviruses. 10:1994;8-13.
10. Fulginiti V. A., Eller J. J., Sieber O. F., Joyner J. W., Minamitani M., Meiklejohn G. Respiratory virus immunization I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine. Am. J. Epidemiol. 89:1969;435-448.
11. Gange S. J., Munoz A., Schrager L. K., Margolick J. B., Giorgi J. V., Saah A. J., Rinaldo C. R., Detels R., Phair J. P. Design of nested studies to identify factors related to late progression of HIV infection. AIDS Res. Hum. Retroviruses. 15:1997;S5-S9.
12. Halstead S. B. Pathogenesis of dengue: challenges to molecular biology. Science. 239:1988;476-481.
13. Halstead S. B., O'Rourke E. J . Antibody-enhances dengue virus infection in primate leukocytes. Nature. 265:1977;739-741.
14. Harrer T., Harrer E., Kalams S. A., Elbeik R., Staprans S. I., Feinberg M. B., Cao Y., Ho D. D., Yilma T., Caliendo A. M., Johnson R. P., Buchbinder S. P., Walker B. D. Strong cytotoxic T cell and weak neutralizing antibody responses in a subset of persons with stable nonprogressing HIV type 1 infection. AIDS Res. Hum. Retroviruses. 12:1996;585-592.
15. Hogervorst E., Jurrians F., de Wolf F., Van Wijk A., Wiersma A., Valk M., Roos M., Van Gemen B., Coutinho R., Miedema F., Goudsmit J. Predictors for non- and slow progession in human immunodeficiency virus (HIV) type 1 infection: Low viral RNA copy numbers in serum and maintenance of high HIV-1 p24-specific but not V3-specific antibody levels. J. Infect. Dis. 171:1995;811-821.
16. Homsy J., Meyer M., Levy J. A. Serum enhancement of human immunodeficiency virus (HIV) infection correlates with disease in HIV-infected individuals. J. Virol. 64:1990;1437-1440.
17. Homsy J., Tateno M., Levy J. A. Antibody-dependent enhancement of HIV infection [letter]. Lancet. 1:1988;1285-1286.
18. Igarashi T., Brown C., Azadegan A., Haigwood N., Dimitrov D., Martin M. A., Shibata R. Human immunodeficiency virus type 1 neutralizing antibodies accelerate clearance of cell-free virions from blood plasma. Nat. Med. 5:1999;211-216.
19. Jolly P. E. Replicative characteristics of primary isolates of the human immunodeficiency virus type 1 in peripheral blood mononuclear cells, primary macrophages and CD4+ transformed T-cell lines. Cell. Mol. Biol. 43:1997;1057-1065.
20. Kliks S. C., Shioda S. T., Haigwood N. L., Levy J. A. V3 variability can influence the ability of an antibody to neutralize or enhance infection by diverse strains of human immunodeficiency virus type 1. Proc. Natl. Acad. Sci.USA. 90:1993;11518-11522.
21. Kostrikis L. G., Cao Y., Ngai H., Moore J. P., Ho D. D. Quantitative analysis of serum neutralization of human immunodeficiency virus type 1 from subtypes A, B, C, D, E, F, and I: Lack of direct correlation between neutralization serotypes and genetic subtypes and evidence for prevalent serum-dependent infectivity enhancement. J. Virol. 70:1996;445-458.
22. Koup R. A., Safrit J. T., Cao Y., Andrews C. A., McLeod G., Borkowsky W., Farthing C., Ho D. D. Temporal association of cellular immune response with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J. Virol. 68:1994;4650-4655.
23. Lehner T., Hussain I., Wilson J., Chapman C. Mucosal transmission of HIV. Nature. 353:1991;709.
24. Mascola J. R., Matthieson B. J., Zack P. M., Walker M. C., Halstead S. B., Burke D. S. Summary report: Workshop on the potential risks of antibody-dependent enhancement in human HIV vaccine trials. AIDS Res. Hum. Retroviruses. 9:1993;1175-1184.
25. Montefiori D. C., Pantaleo G., Fink L. M., Zhou J. T., Zhou J. Y., Bilska M., Miralles G. D., Fauci A. S. Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors. J. Infect. Dis. 173:1996;60-67.
26. Montefiori D. C., Graham B. S., Kliks S., Wright P. F. Serum antibodies to HIV-1 in recombinant vaccinia virus recipients boosted with purified recombinant gp160. J. Clin. Immunol. 12:1992;429-439.
27. Montefiori D. C., Lefkowitz L. B., Keller R. E., Holmberg V., Sandstrom E., Phair J. P. Absence of a clinical correlation for complement-mediated, infection-enhancing antibodies in plasma and sera from HIV-1 infected persons. AIDS. 5:1991;513-517.
28. Montefiori D. C., Murphey-Corb M., Desrosiers R. C., Daniel M. D. Complement-mediated infection-enhancing antibodies in plasma from vaccinated macaques before and after inoculation with live simian immunodeficiency virus. J. Virol. 10:1990;5223-5225.
29. Munoz A., Kirby A. J., He Y. D., Margolick J. B., Visscher B. R., Rinaldo C. R., Kaslow R. A., Phair J. P. Long-term survivors with HIV-1 infection: Incubation period and longitudinal patterns of CD4+ lymphocytes. AIDS Res. Hum. Retroviruses. 8:1995;496-505.
30. Peiris J. S. M., Porterfield J. S. Antibody-mediated enhancement of flavivirus replication in macrophage-like cell lines. Nature. 282:1979;509-511.
31. Pilgrim A. K., Pantaleo G., Cohen O. J. Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection. J. Infect. Dis. 176:1997;924-932.
32. Porterfield J. S. Antibody-dependent enhancement of viral infectivity. Adv. Virus Res. 31:1986;335-355.
33. Rauh L. W., Schmidt R. Measles immunization with killed virus vaccine: Serum antibody titers and experience with exposure to measles epidemic. Am. J. Dis. Child. 109:1965;232-237.
34. Robert-Guroff M., Brown M., Gallo R. C. HTLV-III neutralizing antibodies in patients with AIDS and AIDS-related complex. Nature. 316:1986;72-74.
35. Robinson W. E. Jr., Montefiori D. C., Mitchell W. M. Antibody-dependent enhancement of human immunodeficiency virus typw 1 infection. Lancet. 1:1988;790-794.
36. Shibata R., Igarashi T., Haigwood N., Buckler-White A., Ogert R., Ross W., Willey R., Cho M. W., Martin M. A. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nat. Med. 5:1999;204-210.
37. Takeda A., Tuazon C. U., Ennis F. A. Antibody-enhanced infection by HIV-1 via Fc receptor-mediated entry. Science. 242:1988;580-582.
38. Valentin A., Albert J., Fenyo E. M., Asjo B. Dual Tropism for macrophages and lymphocytes is a common feature of primary human immunodeficiency virus type 1 and 2 isolates. J. Virol. 68:1994;6684-6689.
39. Vennema H., de Groot R. J., Harbour D. A., Dalderup M., Gruffydd-Jones T., Horzinek M. C., Spaan W. J. Early death after feline infectious peritonitis virus challenge due to recombinant vaccinia virus immunization. J. Virol. 64:1990;1407-1409.
40. Zhang Y., Fracasso C., Fiore J. R., Bjorndal A., Angarano G., Gringeri A., Fenyo E. M. Augmented serum neutralizing activity against primary human immunodeficiency virus type 1 (HIV-1) isolates in two groups of HIV-1 infected long-term nonprogressors. J. Infect. Dis. 176:1997;1180-1187.
41. Zolla-Pazner S., Alving C., Belshe R., Berman P., Burda S., Chigurupati P., Clements M. L., Duliege A. M., Excler J. L., Hioe C., Kahn J., McElrath M. J., Sharpe S., Sinangil F., Steimer K., Wlaker M. C., Wassef N., Xu S. Neutralization of clade B primary isolate by sera from human immunodeficiency virus-infected recipients of candidate AIDS vaccines. J. Infect. Dis. 175:1997;764-774.